nach oben

Die Radiologie

Erschienen in:

15.06.2016 | Molekulare Bildgebung | Leitthema

Molekulare Bildgebung bei neurologischen Erkrankungen

verfasst von: M. Reimold, Prof. Dr. C. la Fougère

Erschienen in: Die Radiologie | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Magnetresonanztomographie (MRT) weist als Standardverfahren bei neurodegenerativen und neuroonkologischen Fragestellungen eine eingeschränkte Sensitivität und Spezifität auf. Die nuklearmedizinische molekulare Bildgebung mit spezifischen Positronenemissionstomographie(PET)- und single-photon-emission-computed-tomography(SPECT)-Tracern ermöglicht die Darstellung verschiedener molekularer Targets bzw. Stoffwechselprozesse und stellt damit eine wichtige Ergänzung zur MRT dar. Hier sei exemplarisch auf die Darstellung des Aminosäuretransports im Rahmen neuroonkologischer Fragestellungen verwiesen, sowie auf die bereits im präklinischen Stadium der Alzheimer-Demenz nachweisbaren Amyloidablagerungen mit hierfür seit Kurzem zugelassenen PET-Tracern. Dieser Übersichtsbeitrag bespricht die klinische Bedeutung bzw. die Indikationen der folgenden nuklearmedizinischen Untersuchungsverfahren: der Amyloid-PET, der ¹⁸F-Fluordesoxyglucose-PET und der Dopamintransporter-SPECT im Rahmen der Demenzdiagnostik und der Differenzialdiagnose des Parkinsonsyndroms, sowie die Aminosäure-PET für die Diagnostik hirneigener Tumoren und die Somatostatinrezeptorbildgebung bei Meningeomen.

Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, Podlesek D, Eisenhut M, Kratochwil C (2012) Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 39:1409–1415CrossRefPubMed

Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M (1986) Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 16:2–34CrossRefPubMed

Bailey DL, Pichler BJ, Guckel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, Fougere C la, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schafer J, Schafers M, Wehrl HF, Beyer T (2015) Combined PET/MRI: multi-modality multi-parametric imaging is here. Mol Imaging Biol 17:595–608 (Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tubingen, Germany)CrossRefPubMed

Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115–126CrossRefPubMed

Baron JC, Lebrun-Grandie P, Collard P, Crouzel C, Mestelan G, Bousser MG (1982) Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication. J Nucl Med 23:391–399PubMed

Brunnstrom H, Gustafson L, Passant U, Englund E (2009) Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 49:146–149CrossRefPubMed

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

Chetelat G, Desgranges B, Landeau B, Mezenge F, Poline JB, Sayette V de la, Viader F, Eustache F, Baron JC (2008) Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer’s disease. Brain 131:60–71CrossRefPubMed

Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A (1989) (11 C)L-methionine uptake in gliomas. Neurosurgery 25:720–728CrossRefPubMed

10.

Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP (1982) Glucose utilization of cerebral gliomas measured by [18 F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329CrossRefPubMed

11.

Drzezga A (2010) Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med 24:55–66CrossRefPubMed

12.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113CrossRefPubMed

13.

Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Forstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A (2012) Regional expansion of hypometabolism in Alzheimer’s disease follows amyloid deposition with temporal delay. Biol Psychiatry 71:792–797CrossRefPubMed

14.

Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 130:2616–2635CrossRefPubMed

15.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ (2015) Diagnosis of pseudoprogression in patients with glioblastoma using O‑(2-[18 F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging 42:685–695CrossRefPubMed

16.

Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD (2012) Assessment of treatment response in patients with glioblastoma using O‑(2-18 F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057CrossRefPubMed

17.

Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18 F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33CrossRefPubMed

18.

Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519CrossRefPubMed

19.

Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H (2014) (18 F)Flutemetamol amyloid-beta PET imaging compared with (11 C)PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41:290–300CrossRefPubMed

20.

Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C, Winkler C, Weber WA, Tuscher O, Meyer PT (2012) [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 79:1314–1322CrossRefPubMed

21.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Gobel G, Fougere C la, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) 18 F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15:341–351CrossRefPubMedPubMedCentral

22.

Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, Senda M (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34:1936–1943PubMed

23.

James OG, Doraiswamy PM, Borges-Neto S (2015) PET imaging of tau pathology in Alzheimer’s disease and tauopathies. Front Neurol 6:38CrossRefPubMedPubMedCentral

24.

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, Fougere C la (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029CrossRefPubMed

25.

Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, Bartenstein P, Belka C, Kreth FW, Fougere C la (2013) [18 F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging 12:137–147PubMed

26.

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 54:476–490CrossRefPubMed

27.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319CrossRefPubMed

28.

Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384CrossRefPubMed

29.

Fougere C la, Suchorska B, Bartenstein P, Kreth FW, Tonn JC (2011) Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 13:806–819CrossRefPubMedPubMedCentral

30.

Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuwert T, Bock WJ, Stocklin G, Feinendegen LE, Muller-Gartner HW (1997) 3‑[123I]iodo-alpha-methyltyrosine and [methyl-11 C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38:517–522PubMed

31.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D (2014) Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82:1791–1797CrossRefPubMedPubMedCentral

32.

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Hoffken H, Gerstner A, Grosset DG (2009) Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3‑year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 24:500–508CrossRefPubMed

33.

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94CrossRefPubMed

34.

Moulin-Romsee G, D’Hondt E, Groot T de, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K (2007) Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11 C-methionine? Eur J Nucl Med Mol Imaging 34:2082–2087CrossRefPubMed

35.

Niyazi M, Geisler J, Siefert A, Schwarz SB, Ganswindt U, Garny S, Schnell O, Suchorska B, Kreth FW, Tonn JC, Bartenstein P, Fougere C la, Belka C (2011) FET-PET for malignant glioma treatment planning. Radiother Oncol 99:44–48CrossRefPubMed

36.

Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, Takeda A, Itoh M, Sasaki H (2001) [18 F]FDG-PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:447–456CrossRefPubMed

37.

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O‑(2-[18 F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687CrossRefPubMed

38.

Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36:779–787CrossRefPubMed

39.

Pirotte B, Acerbi F, Lubansu A, Goldman S, Brotchi J, Levivier M (2007) PET imaging in the surgical management of pediatric brain tumors. Chns Off J Int Soc Pediatr Neurosurg 23:739–751CrossRef

40.

Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942CrossRefPubMed

41.

Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, Schuller U, Schichor C, Thon N, Tonn JC (2015) Increased 68 Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med 56:347–353CrossRefPubMed

42.

Reardon DA, Wen PY (2015) Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 12:69–70CrossRefPubMed

43.

Reubi JC, Krenning E, Lamberts SW, Kvols L (1993) In vitro detection of somatostatin receptors in human tumors. Digestion 54(Suppl 1):76–83PubMed

44.

Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 19:407–413PubMed

45.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement 11:964–974CrossRefPubMed

46.

Schifter T, Hoffman JM, Hanson MW, Boyko OB, Beam C, Paine S, Schold SC, Burger PC, Coleman RE (1993) Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17:509–561CrossRefPubMed

47.

Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949CrossRefPubMed

48.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Popperl G, Kreth FW, Fougere C la, Weller M, Tonn JC, German Glioma Network (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719CrossRefPubMed

49.

Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K (2008) Diagnostic accuracy of 11 C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699CrossRefPubMed

50.

Thorwarth D, Henke G, Muller AC, Reimold M, Beyer T, Boss A, Kolb A, Pichler B, Pfannenberg C (2011) Simultaneous 68 Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys 81:277–283CrossRefPubMed

51.

Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19:677–683CrossRefPubMed

52.

Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, Deckert M, Heiss WD, Jacobs AH (2009) Methyl-L-11 C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 50:1962–1968CrossRefPubMed

53.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357–367CrossRefPubMed

54.

Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stocklin G (1999) Synthesis and radiopharmacology of O‑(2-[18 F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212PubMed

55.

Yang I, Aghi MK (2009) New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 6:648–657CrossRefPubMed

56.

Yang L, Rieves D, Ganley C (2012) Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med 367:885–887CrossRefPubMed

57.

Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918–1924CrossRefPubMedPubMedCentral

Titel: Molekulare Bildgebung bei neurologischen Erkrankungen
verfasst von: M. Reimold
Prof. Dr. C. la Fougère
Publikationsdatum: 15.06.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Molekulare Bildgebung
Demenz
Meningeome
Gliome
Meningeome
Demenz
Gliome
Gliome
Erschienen in: Die Radiologie / Ausgabe 7/2016
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI: https://doi.org/10.1007/s00117-016-0124-8

Neu im Fachgebiet Radiologie

08.04.2024 | Andrologie | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molekulare Bildgebung bei neurologischen Erkrankungen

Zusammenfassung

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Multiparametrische und molekulare Bildgebung von Brusttumoren mit MRT und PET‑MRT

Molekulare Bildgebung bei Kopf‐﻿Hals‐Tumoren

Stressfrakturen

Hämatoonkologische Bildgebung

Verlaufskontrolle für subsolide Lungenrundherde mit Low‑dose‑CT

Molekulare Bildgebung in der Praxis

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Molekulare Bildgebung bei Kopf‐Hals‐Tumoren